271 related articles for article (PubMed ID: 22860210)
1. Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study.
Wiskerke J; Irimia C; Cravatt BF; De Vries TJ; Schoffelmeer AN; Pattij T; Parsons LH
ACS Chem Neurosci; 2012 May; 3(5):407-17. PubMed ID: 22860210
[TBL] [Abstract][Full Text] [Related]
2. The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184.
Seillier A; Dominguez Aguilar D; Giuffrida A
Pharmacol Biochem Behav; 2014 Sep; 124():153-9. PubMed ID: 24911644
[TBL] [Abstract][Full Text] [Related]
3. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling.
Pan B; Wang W; Long JZ; Sun D; Hillard CJ; Cravatt BF; Liu QS
J Pharmacol Exp Ther; 2009 Nov; 331(2):591-7. PubMed ID: 19666749
[TBL] [Abstract][Full Text] [Related]
4. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors.
Bedse G; Bluett RJ; Patrick TA; Romness NK; Gaulden AD; Kingsley PJ; Plath N; Marnett LJ; Patel S
Transl Psychiatry; 2018 Apr; 8(1):92. PubMed ID: 29695817
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms.
Spradley JM; Guindon J; Hohmann AG
Pharmacol Res; 2010 Sep; 62(3):249-58. PubMed ID: 20416378
[TBL] [Abstract][Full Text] [Related]
7. The effects of fatty acid amide hydrolase and monoacylglycerol lipase inhibitor treatments on lipopolysaccharide-induced airway inflammation in mice.
Abohalaka R; Bozkurt TE; Nemutlu E; Onder SC; Sahin-Erdemli I
Pulm Pharmacol Ther; 2020 Jun; 62():101920. PubMed ID: 32416152
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of monoacylglycerol lipase is associated with passive coping behavior and attenuation of stress-induced dopamine release in the medial prefrontal cortex.
Pavón FJ; Polis IY; Stouffer DG; Cravatt BF; Roberto M; Martin-Fardon R; Rodríguez de Fonseca F; Parsons LH; Serrano A
Neurobiol Stress; 2021 May; 14():100293. PubMed ID: 33490317
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice.
Hruba L; Seillier A; Zaki A; Cravatt BF; Lichtman AH; Giuffrida A; McMahon LR
J Pharmacol Exp Ther; 2015 May; 353(2):261-8. PubMed ID: 25711338
[TBL] [Abstract][Full Text] [Related]
11. Systemic and spinal administration of FAAH, MAGL inhibitors and dual FAAH/MAGL inhibitors produce antipruritic effect in mice.
Yesilyurt O; Cayirli M; Sakin YS; Seyrek M; Akar A; Dogrul A
Arch Dermatol Res; 2016 Jul; 308(5):335-45. PubMed ID: 27126057
[TBL] [Abstract][Full Text] [Related]
12. Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.
Wiebelhaus JM; Grim TW; Owens RA; Lazenka MF; Sim-Selley LJ; Abdullah RA; Niphakis MJ; Vann RE; Cravatt BF; Wiley JL; Negus SS; Lichtman AH
J Pharmacol Exp Ther; 2015 Feb; 352(2):195-207. PubMed ID: 25398241
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Walentiny DM; Vann RE; Wiley JL
Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice.
Ramesh D; Gamage TF; Vanuytsel T; Owens RA; Abdullah RA; Niphakis MJ; Shea-Donohue T; Cravatt BF; Lichtman AH
Neuropsychopharmacology; 2013 May; 38(6):1039-49. PubMed ID: 23303065
[TBL] [Abstract][Full Text] [Related]
15. Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice.
Owens RA; Ignatowska-Jankowska B; Mustafa M; Beardsley PM; Wiley JL; Jali A; Selley DE; Niphakis MJ; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2016 Aug; 358(2):306-14. PubMed ID: 27307500
[TBL] [Abstract][Full Text] [Related]
16. Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.
Thomas A; Okine BN; Finn DP; Masocha W
Biomed Pharmacother; 2020 Sep; 129():110456. PubMed ID: 32603895
[TBL] [Abstract][Full Text] [Related]
17. Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain.
Della Pietra A; Krivoshein G; Ivanov K; Giniatullina R; Jyrkkänen HK; Leinonen V; Lehtonen M; van den Maagdenberg AMJM; Savinainen J; Giniatullin R
J Headache Pain; 2023 Apr; 24(1):38. PubMed ID: 37038131
[TBL] [Abstract][Full Text] [Related]
18. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
[TBL] [Abstract][Full Text] [Related]
19. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.
Ramesh D; Ross GR; Schlosburg JE; Owens RA; Abdullah RA; Kinsey SG; Long JZ; Nomura DK; Sim-Selley LJ; Cravatt BF; Akbarali HI; Lichtman AH
J Pharmacol Exp Ther; 2011 Oct; 339(1):173-85. PubMed ID: 21719468
[TBL] [Abstract][Full Text] [Related]
20. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice.
Nicolussi S; Viveros-Paredes JM; Gachet MS; Rau M; Flores-Soto ME; Blunder M; Gertsch J
Pharmacol Res; 2014 Feb; 80():52-65. PubMed ID: 24412246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
